How much time should I budget?

About 3 hours total, a working session and a review call. We do the heavy lifting.

What if I only want the roadmap, not the build?

That's the Campaign Repositioning Sprint. Ship it yourself, or upgrade to Done-For-You later.

Do you interview my customers?

Optional. We can mine your call recordings, reviews, and won/lost notes instead.

B2B teams spending $20K+/mo on ads whose demos aren't converting.

Book a 30-minute call. We'll tell you straight if it's a fit.

Where Innovaccer's ads lose the buyer

Innovaccer is running 18 live ads on LinkedIn and Google. Their average fit to their own ideal buyer is 6.7 out of 10, and 7 ads need fixing. Each ad below is one of Innovaccer’s real live creatives, read straight from the ad libraries.

Innovaccer’s live ads, scored against their buyer

Connect the data and the outcomes compound, scored 6/10 against Innovaccer’s ideal buyer. Pain is vivid and ICP-relevant but no proof or specific outcome to earn the demo click.
A new NAACOS–Innovaccer survey found 73% of leaders say ACCESS has shifted their, scored 8/10 against Innovaccer’s ideal buyer. Original NAACOS survey data with a sharp CMS ACCESS hook gives VBC leaders a real reason to download.
The ceiling is the context a tool can see, scored 5/10 against Innovaccer’s ideal buyer. Revenue cycle framing is ICP-relevant but the value proposition stays abstract with no proof or concrete outcome.
The ceiling is the context a tool can see, scored 6/10 against Innovaccer’s ideal buyer. Sharp problem framing but no proof or specific outcome to close the argument.
Introducing Nova, the agentic AI analyst for healthcare, built on Gravity by Inn, scored 7/10 against Innovaccer’s ideal buyer. Named product launch with clear ICP role signal.
Point RCM tools each see one slice of the cycle, scored 7/10 against Innovaccer’s ideal buyer. Precise upstream-auth insight lands hard for RCM leaders, but no proof or outcome number to seal conviction.
Found money, with no EHR change, scored 7/10 against Innovaccer’s ideal buyer. Emotionally precise hook on capacity-constrained RCM teams, but no dollar figure or named outcome weakens conviction.
Personalized Care Beyond Every Visit, scored 6/10 against Innovaccer’s ideal buyer. CMS ACCESS Model anchor is a useful segment signal but the value proposition stays generic without an outcome or differentiator.
Enterprise RCM without the enterprise project, scored 7/10 against Innovaccer’s ideal buyer. Staffing-constraint objection is a real CIO and CFO pain, and the phased approach is a credible differentiator, but no proof.
Care That Continues Between Visits, scored 6/10 against Innovaccer’s ideal buyer. Memorable line and CMS ACCESS anchor are solid but the ad stops at aspiration with no outcome or differentiator shown.
The network’s automation stopped at the EHR walls, scored 8/10 against Innovaccer’s ideal buyer. Inside-the-walls-automated, outside-manual contrast names the exact pain of affiliated-but-independent RCM buyers with precision.
More tools can’t fix fragmented data, scored 7/10 against Innovaccer’s ideal buyer. Sharp AHA-sourced stat nails the CFO pain but no proof Innovaccer closes the gap.
Better Patient Support, Without More Work, scored 7/10 against Innovaccer’s ideal buyer. CMS ACCESS Model hook is precise for care management buyers but outcome proof is absent.
The patient experience starts before the first appointment, scored 6/10 against Innovaccer’s ideal buyer. Workflow pain is real and specific but no outcome number or proof makes the demo ask feel premature.
Platform plus one use case is where the ROI shows up, scored 8/10 against Innovaccer’s ideal buyer. Objection-busting copy directly kills the 18-month rip-and-replace fear with a concrete starting point.
Platform plus one use case is where the ROI shows up, scored 7/10 against Innovaccer’s ideal buyer. Same strong objection-handling message as ad 3 but stripped of the 'prior auth or denials' specificity that makes it land.
Point RCM tools each see one slice of the cycle, scored 7/10 against Innovaccer’s ideal buyer. Vivid pain framing of manual patient-record reassembly resonates but no proof or outcome anchors the platform claim.
Mastek runs it on your telephony. No rip-and-replace, scored 6/10 against Innovaccer’s ideal buyer. Mastek co-brand creates role confusion for an Innovaccer ICP audience and no proof backs the AI agent claims.

See Innovaccer’s full live-ad board on AdRoast. Every creative scored against their ICP, with the exact fix for each.

Learn the method behind these scores: the AdRoast guides cover how to audit your ads against your ICP and why clicks do not turn into pipeline.